Ultragenyx Pharmaceutical Inc. (RARE)
USD 42.94
(-4.47%)
USD 42.94
(-4.47%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -474.8 Million | -380.46 Million | -338.69 Million | -132.22 Million | -345.38 Million | -290.56 Million |
| Net Income | -606.63 Million | -707.42 Million | -454.02 Million | -186.56 Million | -402.72 Million | -197.61 Million |
| Depreciation & Amortization | 26 Million | 18.22 Million | 13.23 Million | 12.26 Million | 8.53 Million | 19.53 Million |
| Deferred income taxes | -1.61 Million | -1.63 Million | 48.66 Million | -169.77 Million | -18.93 Million | -167.65 Million |
| Stock-based compensation | 135.21 Million | 130.37 Million | 104.95 Million | 85.73 Million | 81.99 Million | 80.1 Million |
| Change in working capital | -15.1 Million | 60.23 Million | -63.23 Million | 104.66 Million | -15.94 Million | -24.79 Million |
| Other non-cash items | -12.68 Million | 119.76 Million | 11.7 Million | 21.46 Million | 1.69 Million | -156 Thousand |
| Investing Cash Flow | 168 Million | -291.65 Million | -195.37 Million | -179.12 Million | -13.03 Million | -33.33 Million |
| Investments in PPE | -46.76 Million | -146.12 Million | -73.09 Million | -43.9 Million | -24.83 Million | -4.07 Million |
| Acquisitions | -2.5 Million | -75.02 Million | - | - | -11.79 Million | - |
| Investment purchases | -526.38 Million | -614.73 Million | -1.01 Billion | -850.29 Million | -707.16 Million | -509.79 Million |
| Sales/Maturities of investments | 746.19 Million | 545.07 Million | 890.85 Million | 720.63 Million | 718.95 Million | 310.21 Million |
| Other Investing Activities | -2.54 Million | -844 Thousand | -942 Thousand | -5.55 Million | 11.79 Million | 170.32 Million |
| Financing Cash Flow | 388.14 Million | 501.2 Million | 118.55 Million | 600.27 Million | 679.3 Million | 336.85 Million |
| Debt repayment | - | -490.95 Million | - | - | -314.23 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 388.17 Million | 10.81 Million | 78.94 Million | 511.21 Million | 365.07 Million | 336.85 Million |
| Other Financing Activities | 388.14 Million | 981.34 Million | 39.6 Million | 89.05 Million | 679.3 Million | 336.85 Million |
| Accounts receivables | -22.77 Million | -12.06 Million | -5.43 Million | 9.84 Million | -20.1 Million | -7.58 Million |
| Accounts payables | 2.38 Million | 87.44 Million | 2.8 Million | 29.6 Million | 20.64 Million | 3.37 Million |
| Inventory | -6.93 Million | -9.7 Million | -3.11 Million | -1.34 Million | -4.45 Million | -5.28 Million |
| Other working capital | 12.22 Million | -5.43 Million | -57.49 Million | 66.56 Million | -12.03 Million | -15.29 Million |
| Cash at beginning of period | 133.8 Million | 309.58 Million | 726.29 Million | 436.24 Million | 115.52 Million | 103.04 Million |
| Cash at end of period | 219.39 Million | 137.6 Million | 309.58 Million | 726.29 Million | 436.24 Million | 115.52 Million |
| Capital Expenditure | -46.76 Million | -146.12 Million | -73.09 Million | -43.9 Million | -24.83 Million | -4.07 Million |
| Effect of forex changes on cash | 462 Thousand | -1.07 Million | -1.19 Million | 1.11 Million | -165 Thousand | -472 Thousand |
| Net cash flow / Change in cash | 85.59 Million | -171.98 Million | -416.7 Million | 290.05 Million | 320.71 Million | 12.48 Million |
| Free Cash Flow | -521.57 Million | -526.58 Million | -411.78 Million | -176.12 Million | -370.21 Million | -294.64 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -131.59 Million | -170.68 Million | -123.19 Million | -606.63 Million | -159.64 Million | -159.82 Million |
| Depreciation & Amortization | 8.86 Million | 8.84 Million | 8.21 Million | 26 Million | 7.19 Million | 5.36 Million |
| Deferred income taxes | - | - | -139.17 Million | -1.61 Million | -1.26 Million | -3.48 Million |
| Stock-based compensation | 39.36 Million | 36.92 Million | 33.74 Million | 135.22 Million | 34.87 Million | 34.65 Million |
| Change in working capital | 16.35 Million | -56.01 Million | 13.3 Million | -15.1 Million | 2.8 Million | 7.15 Million |
| Other non-cash items | 23.77 Million | 107.39 Million | 123.19 Million | -12.68 Million | -1.83 Million | -27 Thousand |
| Investing Cash Flow | 60.56 Million | 94.43 Million | -107.01 Million | 168 Million | 64.29 Million | 99.41 Million |
| Investments in PPE | -4.5 Million | -13.21 Million | -1.6 Million | -46.76 Million | -3.69 Million | -16.43 Million |
| Acquisitions | - | - | 2.5 Million | -2.5 Million | - | -2.5 Million |
| Investment purchases | -3.37 Million | -21.92 Million | -221.59 Million | -526.38 Million | -139.48 Million | -103.28 Million |
| Sales/Maturities of investments | 68.48 Million | 131.63 Million | 116.44 Million | 746.19 Million | 207.9 Million | 219.53 Million |
| Other Investing Activities | -41 Thousand | -2.06 Million | -271 Thousand | -2.54 Million | -428 Thousand | 2.1 Million |
| Financing Cash Flow | 384.93 Million | -58 Thousand | 330.61 Million | 388.14 Million | 25.23 Million | 33.02 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 58 Thousand | -58 Thousand | - | - | - | - |
| Common Stock Issuance | 384.88 Million | -58 Thousand | 383.9 Million | 388.17 Million | 442 Thousand | 3.06 Million |
| Other Financing Activities | 384.93 Million | -58 Thousand | 330.61 Million | 388.14 Million | 25.23 Million | 33.02 Million |
| Accounts receivables | 2.15 Million | -24.9 Million | 1.01 Million | -22.77 Million | -6.2 Million | -15.07 Million |
| Accounts payables | 25.32 Million | -35.54 Million | 15.86 Million | 2.38 Million | 7.48 Million | 11.78 Million |
| Inventory | -4.12 Million | -2.12 Million | -1.95 Million | -6.93 Million | -3.46 Million | -1.65 Million |
| Other working capital | -7 Million | 6.55 Million | -1.61 Million | 12.22 Million | 4.99 Million | 12.11 Million |
| Cash at beginning of period | 118.55 Million | 215.59 Million | 74.55 Million | 133.8 Million | 107.66 Million | 91.52 Million |
| Cash at end of period | 486.86 Million | 118.55 Million | 219.39 Million | 219.39 Million | 78.6 Million | 107.66 Million |
| Capital Expenditure | -4.5 Million | -13.21 Million | -1.6 Million | -46.76 Million | -3.69 Million | -16.43 Million |
| Effect of forex changes on cash | -648 Thousand | -679 Thousand | 1.1 Million | 462 Thousand | -716 Thousand | -136 Thousand |
| Net cash flow / Change in cash | 368.31 Million | -97.03 Million | 144.84 Million | 85.59 Million | -29.06 Million | 16.14 Million |
| Free Cash Flow | -81.47 Million | -203.93 Million | -85.5 Million | -521.57 Million | -121.56 Million | -132.59 Million |
2941
011090
MILDEF
605116
7501